WKL Wolters Kluwer NV

Vermont Health Information Exchange Leverages Terminology and Data Management Solutions from Wolters Kluwer to Support Population Health and ACO Analytics

Wolters Kluwer, a leading global provider of information and point of care solutions for the healthcare industry, announced today a partnership with Vermont Information Technology Leaders (VITL) to advance health information exchange and accountable care reporting for the state.

Under the partnership, VITL implemented Wolters Kluwer’s Health Language® Enterprise Terminology Management Platform to enhance its core interoperability systems and expand its capabilities to support ACOs, patient-centered medical homes (PCMHs), health plans and healthcare providers with medication reconciliation, data analytics, quality reporting and population health management.

“Data quality is crucial to our ACO, OneCare Vermont, and our Blueprint for Health patient-centered medical home,” said Michael Gagnon, Chief Technology Officer at VITL. “The Health Language platform plays a major part in helping us normalize specific quality measures for these customers.”

“We are delighted to be supporting VITL and their stakeholders with their advanced interoperability and quality reporting initiatives,” said Dan Buell, General Manager of Health Language at Wolters Kluwer Clinical Software Solutions. “Hundreds of thousands of people are benefitting from improved patient care and population health advancements as a result of VITL and its health information management capabilities. It’s exciting and rewarding to be contributing to such an important initiative at the leading edge of healthcare transformation.”

The Enterprise Terminology Management Platform is a comprehensive solution for synthesizing and managing big data across the healthcare continuum, enabling accurate analytics and reporting. It helps healthcare organizations enhance investments made in data warehouses, analytics software and population health management tools by standardizing and normalizing clinical, claims and administrative data across disparate systems. Additionally, the platform helps healthcare organizations manage data governance and centralize healthcare terminologies such as standard code sets used for clinical, billing and administrative documentation and reporting.

For more information about the Health Language Enterprise Terminology Management Platform, please visit www.healthlanguage.com.

About Wolters Kluwer

Wolters Kluwer N.V. (AEX:WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our solutions and organization, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

EN
20/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Wolters Kluwer NV

Wolters Kluwers: 1 director

A director at Wolters Kluwers maiden bought 1,875 shares at 131.520USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

 PRESS RELEASE

Share Buyback Transaction Details August 7 – August 13, 2025

Share Buyback Transaction Details August 7 – August 13, 2025 PRESS RELEASE                                         Share Buyback Transaction Details August 7 – August 13, 2025 Alphen aan den Rijn – August 14, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 137,900 of its own ordinary shares in the period from August 7, 2025, up to and including August 13, 2025, for €16.2 million and at an average share price of €117.75. These repurchases are part of the share buyback program announc...

 PRESS RELEASE

Share Buyback Transaction Details July 31 – August 6, 2025

Share Buyback Transaction Details July 31 – August 6, 2025 PRESS RELEASE                                         Share Buyback Transaction Details July 31 – August 6, 2025 Alphen aan den Rijn – August 7, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 109,700 of its own ordinary shares in the period from July 31, 2025, up to and including August 6, 2025, for €14.5 million and at an average share price of €132.48. These repurchases are part of the share buyback program announced on...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

CTP: Good results, continuation of strong demand dynamics. KBC: 2025 outlook, strong uplift post 2Q. RELX, Wolters Kluwer: Thomson Reuters 2Q25 results. SBM Offshore: Guidance up, one-offs play a role. Xior Student Housing: On track, continued focus on pricing and pipeline

David Vagman ... (+5)
  • David Vagman
  • CFA
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Wolters Kluwer/Solid start to the year/BUY

Wolters Kluwer reported a solid 1H25 update. We make small adjustments to our organic growth and margin forecasts, but it is mainly FX headwinds that bring down our top-line estimates by low-single-digit percentages in the coming years. We reiterate our BUY rating and lower our target price per share to €173 (from €178).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch